-
公开(公告)号：US12110313B2
公开(公告)日：2024-10-08
申请号：US16804691
申请日：2020-02-28
Applicant: Sidney Hecht , Larisa Dedkova , Shengxi Chen , Xiaoguang Bai
Inventor： Sidney Hecht , Larisa Dedkova , Shengxi Chen , Xiaoguang Bai
IPC: C07K14/00 , C07H19/16 , C07K14/565
CPC classification number: C07K14/001 , C07H19/16 , C07K14/565
Abstract: Compositions and methods relating to bacterial ribosomes selected to increase the incorporation of at least one glycosylated amino acid into a protein versus a wild-type bacterial ribosome. Selection embodiments include growing bacteria in the presence of a puromycin derivative, wherein a surviving clone has a ribosome that incorporates at least one glycosylated amino acid into a protein.
-
公开(公告)号：US20240301002A1
公开(公告)日：2024-09-12
申请号：US18590524
申请日：2024-02-28
Applicant: SYMTHERA CANADA LTD.
Inventor： Chai EZERZER
Abstract: Presented herein are cancer peptide agents and uses thereof for treating cancer and/or inhibiting metastasis. Also presented herein are methods of treating cancer, or inhibiting metastasis of cancer in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents to the subject. Also presented herein is a method of treating a cancer in a subject, or inhibiting metastasis of a cancer in a subject that comprises administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents, and administering a chemotherapy or chemotherapeutic agent.
-
公开(公告)号：US20240294575A1
公开(公告)日：2024-09-05
申请号：US18600801
申请日：2024-03-11
Applicant: REJUKON BIOPHARM INC.
Inventor： Chenchen WANG
CPC classification number: C07K14/001 , A61P25/28 , C12N15/86 , A61K38/00 , A61K48/00 , C12N2750/14143
Abstract: The present disclosure provides a polypeptide capable of dissolving protein aggregates. Also provided is a method of treating a neurodegeneration disease using the polypeptide.
-
4.发明公开
公开(公告)号：US20240279285A1
公开(公告)日：2024-08-22
申请号：US18570390
申请日：2022-06-17
Applicant: The Regents of the University of California
Inventor： Jevgenij A. Raskatov
IPC: C07K14/00
CPC classification number: C07K14/001
Abstract: Provided are rippled antiparallel cross-β dimers. In some embodiments, the dimers comprise (L,L,L)-(FX1F)k dimerized with (D,D,D)-(FX2F)k, where X1 and X2 are independently selected from any amino acid, and wherein k is an integer of 1 or greater. Also provided are rippled β-sheet fibrils comprising a plurality of the rippled antiparallel cross-β dimers of the present disclosure. Materials comprising the rippled antiparallel cross-β dimers and rippled β-sheet fibrils of the present disclosure are also provided, as are compositions comprising such materials. Also provided are methods of making the rippled antiparallel cross-β dimers and rippled β-sheet fibrils of the present disclosure.
-
公开(公告)号：US20240269230A1
公开(公告)日：2024-08-15
申请号：US17912907
申请日：2021-03-19
Applicant: MEDIZINISCHE UNIVERSITAT WIEN
Inventor： Christian Gruber , Edin Muratspahic
CPC classification number: A61K38/168 , A61K38/33 , C07K14/001
Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide and a ligand of the kappa opioid receptor (the kOR), or a combination thereof, for use in treating Multiple Sclerosis (MS), in remyelination, in improving CNS lesions, in preventing or reducing demyelination and/or CNS lesions, and/or in treating pain, in particular neuropathic pain and/or pain resulting from/coming along with MS. The present invention further relates to a combination of a cyclotide and a ligand of the kOR and to a pharmaceutical composition comprising said combination. The present invention further relates to a use of a cyclotide for reducing adverse effects of a ligand of the kOR and/or for increasing the potency and/or efficacy of a ligand of the kOR. Further, the present invention relates to a kit comprising a cyclotide and a ligand of the kOR. The present invention further relates to a pharmaceutical composition as part of a kit, wherein a comprised cyclotide and ligand of the kOR are for use in treating MS and related diseases and/or symptoms. The present invention further relates to a kit comprising a pharmaceutical composition comprising a cyclotide and a ligand of the kOR, wherein said pharmaceutical composition and/or said cyclotide and ligand of the kOR is/are for use in treating MS and related diseases and/or symptoms. The invention further relates to (a) novel Viola-type cyclotide(s).
-
公开(公告)号：US20240247034A1
公开(公告)日：2024-07-25
申请号：US18497741
申请日：2023-10-30
Applicant: Genentech, Inc.
Inventor： Rami HANNOUSH , Harini KALUARACHCHI , Aaron NILE , Cameron NOLAND , Yingnan ZHANG , Lijuan ZHOU , Xinxin GAO
IPC: C07K14/415 , A61K9/00 , A61K9/50 , A61K38/00 , A61K38/16 , A61K47/34 , C07K14/00 , C07K14/47 , C07K14/81
CPC classification number: C07K14/415 , A61K9/0051 , A61K9/5031 , A61K38/00 , A61K38/168 , A61K47/34 , C07K14/001 , C07K14/4702 , C07K14/811 , C07K2319/70
Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
-
公开(公告)号：US12042524B2
公开(公告)日：2024-07-23
申请号：US17231981
申请日：2021-04-15
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
CPC classification number: A61K38/02 , A61K38/16 , C07K14/001 , C07K14/47 , C07K16/2863 , A61K38/00 , C07K5/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US12036271B2
公开(公告)日：2024-07-16
申请号：US17838017
申请日：2022-06-10
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Anita Wiebe , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K38/08 , A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/08 , C07K7/06 , C07K7/08 , C07K14/001 , C07K14/70539 , C07K16/2833 , C12N5/0638 , C12N15/115 , A61K2039/5158 , C07K2319/00 , C12N2310/16 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/515
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240228603A1
公开(公告)日：2024-07-11
申请号：US18400894
申请日：2023-12-29
Applicant: CytomX Therapeutics, Inc.
Inventor： Nancy Elizabeth STAGLIANO , James William WEST , Kathryn KAMATH , Paul Henry BESSETTE , Fred GLUCK , Jason Gary SAGERT , Patrick DAUGHERTY
IPC: C07K16/22 , A61K39/00 , A61K39/395 , A61K47/68 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/30 , G01N33/68
CPC classification number: C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , G01N33/6845 , G01N33/6854 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50
Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
-
公开(公告)号：US20240209029A1
公开(公告)日：2024-06-27
申请号：US18555201
申请日：2021-04-21
Applicant: The University of Hong Kong
Inventor： Yu WANG , Xuechen LI , Aimin XU , Hongxiang WU , Yiwei ZHANG , Yuanxin LI
CPC classification number: C07K14/001 , A61P3/04 , A61P3/10 , A61P35/00 , B01J23/50 , C07K1/1075 , C07K14/575 , A61K38/00
Abstract: An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/yield compared to conventional methods. In particular, a method for the large-scale, chemical synthesis of hydroxylated amino acid building blocks and glycosylated amino acids suitable for solid phase peptide synthesis (SPPS) are disclosed. SPPS-based methods using the glycosylated amino acids to chemically synthesize adiponectin-like peptides are also described. In vivo studies show that the adiponectin mimicking glycopeptides exhibit significant anticancer, anti-obesity and insulin sensitizing effects. Pharmaceutical compositions of the synthetic glycopeptides and methods of use thereof in treating diseases associated with deficient adiponectin are also described.
